The short version
Sunlight is a flat-rate telehealth provider. As of the August 25, 2026 build, for tirzepatide its lowest 12-month all-in total is $1,884 (month-to-month plan, verified), which places it 6 of 30 ranked telehealth providers; for semaglutide its lowest 12-month all-in total is $1,056 (month-to-month plan, verified), which places it 1 of 13 ranked telehealth providers. Verification status: verified.
The numbers, plan by plan
- Semaglutide (standard, injection, month-to-month plan): $88 per month (the price at higher doses is not published). Status: verified, checked August 25, 2026. Flat monthly pricing "starting at" $88 for semaglutide including prescription and support.
- Tirzepatide (standard, injection, month-to-month plan): $157 per month (the price at higher doses is not published). Status: verified, checked August 25, 2026. Flat monthly pricing "starting at" $157 for tirzepatide including prescription and ongoing support; the directory's $239 is outdated. Whether $157 holds at every dose is not stated.
Fees and what the price includes
The published price includes the medication and clinical care, with no separate membership fee. Shipping terms are not published in the sources we hold. Consultation terms are not published. Whether the price changes with dose is not confirmed.
How this pricing structure plays out over a year
The price at 10 and 15 mg is not published. Most patients reach those doses by month six, so the twelve-month total shown assumes the starting price holds and is a floor, not a quote.
Compared with the field
On tirzepatide, Sunlight's lowest twelve-month total of $1,884 is $384 above the lowest (Trimi, $1,500) and below the median of $3,090 across 30 ranked providers, placing it 6 of 30. On the value score it scores 71 against 92 for NexLife, the best-scoring provider; the gap comes from transparency, flexibility, care. On semaglutide, Sunlight's lowest twelve-month total of $1,056 is the lowest in the database and below the median of $2,100 across 13 ranked providers, placing it 1 of 13. On the value score it scores 71 against 92 for NexLife, the best-scoring provider; the gap comes from transparency, flexibility, care.
Pharmacy, coverage and cancellation
The provider reports serving all fifty states. The dispensing pharmacy and its 503A or 503B status are not published; ask at intake and verify the license. Commitment: month-to-month reported. Cancellation: not captured.
Questions to ask Sunlight before paying
Ask, in writing: Which pharmacy fills the prescription, is it 503A or 503B, and can I see a certificate of analysis for my batch? What is the all-in price at 7.5, 10, 12.5 and 15 mg? Is there any membership, program, consultation or shipping fee beyond the medication price? How do I cancel, how much notice is required, and is there a fee? Will my dosing instructions state the concentration of the vial you actually ship, and will you reissue them if it changes? A provider that answers all of these promptly is operating in the open; one that will not name its pharmacy has answered the most important question.
What works
Advertised starting prices are among the lowest published for both drugs. Prescription and ongoing support included.
What to weigh against it
"Starting at" language; the price at higher doses and any plan-length conditions are not published. Pharmacy not named.
Who should choose Sunlight
Patients comparing mid-to-upper market flat prices. A patient with insurance coverage for Zepbound or Wegovy should compare the copay route first; a patient who wants a verified flat all-in price with month-to-month flexibility should compare the best overall provider on our value score; and any patient should ask which pharmacy fills the prescription before paying.
How we verified this
Sunlight's site advertises flat monthly pricing starting at $88 for semaglutide and $157 for tirzepatide, including prescription and ongoing support; the directory's $239 is outdated. No named dispenser or unambiguous 503A/503B assignment is published. Verified against the provider's own pages on 2026-08-25 (first-party verification pass).